TABLE 2.
Other outcomes.
| Outcomes | Subgroup | Number of studies | Mean difference or risk ration (95%CI) | Test for effect (p value) | Heterogeneity | |
|---|---|---|---|---|---|---|
| I2 (p value) | ||||||
| Discontinuation rate | NDD-CKD | 3 [24,26,27] | 1.53 [0.27, 8.86] | 0.63 | 52% (0.12) | |
| DD-CKD | 3 [22,23,25] | 2.93 [0.53, 16.06] | 0.22 | 0% (0.60) | ||
| △Hepcidin (ng/ml) | NDD-CKD | 3 [24,26,27] | −32.62 [−54.75, −10.49] | <0.01 | 90% (< 0.01) | |
| DD-CKD | 4 [22,23,25,28] | −9.26 [−33.69, 15.16] | 0.46 | 87% (< 0.01) | ||
| △Ferritin (ng/ml) | NDD-CKD | 3 [24,26,27] | −20.18 [−31.73, −8.64] | <0.01 | 0% (0.76) | |
| DD-CKD | 4 [22,23,25,28] | −22.80 [−61.94, 16.34] | 0.25 | 76% (< 0.01) | ||
| △Total iron-binding capacity (ug/dL) | NDD-CKD | 3 [24,26,27] | 29.00 [19.65, 38.35] | <0.01 | 70% (0.04) | |
| DD-CKD | 4 [22,23,25,28] | 33.85 [25.06, 42.64] | <0.01 | 76% (< 0.01) | ||
| △Transferrin saturation (%) | NDD-CKD | 3 [24,26,27] | -9.71 [−19.94, 0.52] | 0.06 | 48% (0.14) | |
| DD-CKD | 4 [22,23,25,28] | 2.64 [0.31, 4.97] | 0.03 | 0% (0.92) | ||
| △Total iron (ug/dL) | NDD-CKD | 3 [24,26,27] | −2.10 [−3.71, −0.49] | 0.01 | 0% (0.59) | |
| DD-CKD | 4 [22,23,25,28] | 11.46 [9.74, 13.19] | <0.01 | 0% (0.48) | ||
| IV iron therapy rate | NDD-CKD | 2 [24,26] | 1.72 [0.79, 3.75] | 0.17 | 0% (0.72) | |
| DD-CKD | 2 [22,25] | 0.88 [0.65, 1.20] | 0.42 | 59% (0.12) | ||
| Outcomes | Subgroup | Number of studies | Value | Study | Maximum observed VEGFb | Test for effect (p value) |
| VEGF levels (ng/L) | NDD-CKD | 1 [24] | T: 65.8 (17.9, 467.9)a | [24] | T:105.8 (33.1,1205.3) | >0.05 |
| C: 68.7 (22.9, 1118.5)a | C:94.5 (25.5, 472.7) | |||||
| DD-CKD | 2 [23,25] | T: 2.03 ± 65.63b | [23] | NA | >0.05 | |
| C: 1.2 ± 40.3b | [25] | T: 270.0 (81.8, 808.3) | >0.05 | |||
| T: 186.9 (64.3, 1142.6)a | C: 269.4 (98.7, 924.0) | |||||
| C: 220.0 (78.2, 595.7)a |
Abbreviations: C, control group; CI, confidence interval; CKD, chronic kidney disease; DD, dialysis-dependent; IV, intravenous; NA, not available; NDD, non-dialysis-dependent; rhEPO, recombinant human erythropoietin; T, treatment group; VEGF, vascular endothelial growth factor; a baseline, median (minimum, maximum); b change from baseline (mean ± SD).